undamentalytics Newsletter
Sign in

Fortress Biotech, Inc. cash flow statement

In fiscal 2025, Fortress Biotech, Inc.'s operations generated −$65.8m of cash; it spent $0 on capital projects, leaving free cash flow of −$65.8m. It returned $664,000 in dividends.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−30−16−20−46−81−99−95−84−117−179−128−80−66126
Depreciation and amortisation00011122332100
Stock-based pay66141213151313192317332910
Capital spending00061722530000
Free cash flow−30−16−21−52−82−106−97−86−121−182−128−80−66126
Free cash flow after stock pay−36−22−35−64−95−121−110−99−141−205−145−113−95116
Dividends paid——————0011111—
Share buybacks——————00——————
Shares issued91400—10214696241—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FBIO vs RXRXCYTK vs FBIOABCL vs FBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fortress Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fortress Biotech, Inc.